THE EFFECTS OF THE PHASES OF ANTI-TUBERCULOSIS DRUG (OAT) CONSUMPTION ON AST AND ALT ENZYME LEVEL OF PATIENTS WITH PULMONARY TUBERCULOSIS

Abstract

ulmonary tuberculosis became one of the ten biggest diseases that caused mortality. In Indonesia, it was ranked second to cause mortality. WHO recommended treatment with anti-tuberculosis drugs (OAT) for at least six months. The treatment consisted of intensive phase (two months) and advanced phase (four months). Long-term treatment might have side effects on liver because OAT was hepatotoxic. The purpose of this research was to find out the effect of anti-tuberculosis drug consumption phase on AST and ALT enzyme levels to monitor hepatotoxic risk. This research was based on secondary examination results on AST and ALT enzyme on 60 patients with pulmonary tuberculosis at Persahabatan Hospital. It was conducted using cross sectional method with statistic Friedman and Wilcoxon Sign Test. AST enzyme levels before treatment, during intensive phase, and during advanced phase were 18.20 U/L, 38.80 U/L, and 24.33 U/L respectively. Meanwhile ALT enzyme levels before treatment, during intensive phase, and during advanced phase were 13.60 U/L, 28.07 U/L, and 14.98 U/L respectively. There was a difference among AST and ALT enzyme levels between before treatment, that during intensive phase, and that during advanced phase (P = 0.000 < 0.05), except ALT level before treatment and during advanced phase (P = 0.317 > 0.05). The findings indicated the effects of anti-tuberculosis drug on AST and ALT levels of patients with tuberculosis. The treatment given during the intensive phase gave the highest hepatotoxic effect. It was because in the phase, combination and frequency of OAT were more than that in the advanced phase.